Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of IntegraMed America, Inc (“IntegraMed” or the “Company”) (Nasdaq: INMD) relating to the proposed acquisition by Sagard Capital Partners. (“Sagard”). Under the terms of the transaction, IntegraMed shareholders will receive $14.05 in cash for each share of IntegraMed stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of IntegraMed for not acting in the Company’s shareholders' best interests in connection with the sale process to Sagard. The transaction will not result in a substantial premium above the $13.50 that IntegraMed stock traded at on April 16, 2012 and is below a $17.00 analyst target price for IntegraMed stock. If you own shares of IntegraMed stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com visiting http://brodsky-smith.com/435-inmd-integramed-america-inc.html, or by calling toll free 877-LEGAL-90.
Shares of IntegraMed America (Nasdaq:INMD) have taken a tremendous swing upward. The stock is trading at $13.71 as of 9:55 a.m. ET, 20.9% above Friday's closing price of $11.34. Volume is at 476,658, 22.5 times the daily average of 21,200.